GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pet Pharm Biotech Co Ltd (ROCO:7762) » Definitions » Equity-to-Asset

Pet Pharm Biotech Co (ROCO:7762) Equity-to-Asset : 0.77 (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Pet Pharm Biotech Co Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Pet Pharm Biotech Co's Total Stockholders Equity for the quarter that ended in Dec. 2024 was NT$582.5 Mil. Pet Pharm Biotech Co's Total Assets for the quarter that ended in Dec. 2024 was NT$760.1 Mil. Therefore, Pet Pharm Biotech Co's Equity to Asset Ratio for the quarter that ended in Dec. 2024 was 0.77.

The historical rank and industry rank for Pet Pharm Biotech Co's Equity-to-Asset or its related term are showing as below:

ROCO:7762' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.7   Med: 0.77   Max: 0.85
Current: 0.77

During the past 3 years, the highest Equity to Asset Ratio of Pet Pharm Biotech Co was 0.85. The lowest was 0.70. And the median was 0.77.

ROCO:7762's Equity-to-Asset is ranked better than
76.74% of 1023 companies
in the Drug Manufacturers industry
Industry Median: 0.61 vs ROCO:7762: 0.77

Pet Pharm Biotech Co Equity-to-Asset Historical Data

The historical data trend for Pet Pharm Biotech Co's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pet Pharm Biotech Co Equity-to-Asset Chart

Pet Pharm Biotech Co Annual Data
Trend Dec22 Dec23 Dec24
Equity-to-Asset
0.70 0.85 0.77

Pet Pharm Biotech Co Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24
Equity-to-Asset 0.70 - 0.85 0.74 0.77

Competitive Comparison of Pet Pharm Biotech Co's Equity-to-Asset

For the Drug Manufacturers - General subindustry, Pet Pharm Biotech Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pet Pharm Biotech Co's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pet Pharm Biotech Co's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Pet Pharm Biotech Co's Equity-to-Asset falls into.


;
;

Pet Pharm Biotech Co Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Pet Pharm Biotech Co's Equity to Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Equity to Asset (A: Dec. 2024 )=Total Stockholders Equity/Total Assets
=582.543/760.06
=0.77

Pet Pharm Biotech Co's Equity to Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

Equity to Asset (Q: Dec. 2024 )=Total Stockholders Equity/Total Assets
=582.543/760.06
=0.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pet Pharm Biotech Co  (ROCO:7762) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Pet Pharm Biotech Co Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Pet Pharm Biotech Co's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Pet Pharm Biotech Co Business Description

Traded in Other Exchanges
N/A
Address
143, Hougang 1st Road, 1-2F., No. 141, Xinzhuang District, New Taipei City, TWN, 242051
Pet Pharm Biotech Co Ltd is a Pharmaceutical company. The company is engaged in manufacturing medicinal products and medicine drugs. The products offered by the company include FDG Fluodeoxyglucose Injection (18F-FDG), Naolixi Injection (18F-FBB), Sodium fluoride injection (18F-NaF), and others.

Pet Pharm Biotech Co Headlines

No Headlines